Literature DB >> 22194161

Association between E-cadherin (CDH1) polymorphisms and papillary thyroid carcinoma risk in Han Chinese population.

Ying-Xue Wang1, Lei Zhao, Xiu-Yun Wang, Chang-Mei Liu, Su-Guo Yu.   

Abstract

The aim of this study is to investigate the associations between E-cadherin gene (CDH1) polymorphisms and papillary thyroid carcinoma (PTC) risk predisposition. We undertook a case-control study to analyze three CDH1 polymorphisms (+54T>C, -160C>A, and -347G→GA) in an Han Chinese population, by extraction of genomic DNA from the peripheral blood of 98 patients with PTC and 176 control participants, and performed CDH1 genotyping using DNA sequencing. The obtained results indicated that overall, no statistically significant association was observed in +54T>C. Nevertheless, -347G→GA genotype was at increased risk of PTC (P = 0.001; odds ratio (OR) = 2.12, CI 95%:1.24-3.34). Furthermore, -347GA/GA genotype thyroid cancers were more significantly common in patients with tumor size of ≥20 mm than G or G/GA genotypes PTC and in cases of advanced T stage. However, -160C>A genotype demonstrated a protective effect in PTCs (P = 0.006; OR = 0.59, CI 95%: 0.42-0.87). These findings led us to conclude that polymorphism in -347G→GA was observed to be associated with susceptibility of PTC. However, -160C>A polymorphism indicated to play a protective role in susceptibility to PTC. Nevertheless, further investigation with a larger sample size is needed to support our results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22194161     DOI: 10.1007/s12020-011-9582-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  34 in total

1.  Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant.

Authors:  A S Rocha; P Soares; R Seruca; V Máximo; X Matias-Guiu; J Cameselle-Teijeiro; M Sobrinho-Simões
Journal:  J Pathol       Date:  2001-07       Impact factor: 7.996

2.  [Epidemiology, pathophysiology, guideline-adjusted diagnostics, and treatment of thyroid nodules].

Authors:  Ralf Paschke; Kurt Werner Schmid; Roland Gärtner; Klaus Mann; Henning Dralle; Christian Reiners
Journal:  Med Klin (Munich)       Date:  2010-02-20

Review 3.  Cadherins in neuronal morphogenesis and function.

Authors:  Sachihiro C Suzuki; Masatoshi Takeichi
Journal:  Dev Growth Differ       Date:  2008-04-22       Impact factor: 2.053

4.  Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region.

Authors:  Akihiro Nakamura; Tomoe Shimazaki; Kazuhiro Kaneko; Minoru Shibata; Takuya Matsumura; Maho Nagai; Reiko Makino; Keiji Mitamura
Journal:  Mutat Res       Date:  2002-05-22       Impact factor: 2.433

5.  E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.

Authors:  A Mitselou; E Ioachim; D Peschos; K Charalabopoulos; M Michael; N J Agnantis; T Vougiouklakis
Journal:  Exp Oncol       Date:  2007-03

6.  E-cadherin gene alterations are rare events in thyroid tumors.

Authors:  P Soares; G Berx; F van Roy; M Sobrinho-Simões
Journal:  Int J Cancer       Date:  1997-01-06       Impact factor: 7.396

7.  Is ionizing radiation responsible for the increasing incidence of thyroid cancer?

Authors:  Yuri E Nikiforov
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

8.  CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk.

Authors:  Haixin Lei; Sara Sjöberg-Margolin; Sima Salahshor; Barbro Werelius; Eva Jandáková; Kari Hemminki; Annika Lindblom; Igor Vorechovský
Journal:  Int J Cancer       Date:  2002-03-10       Impact factor: 7.396

9.  E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas.

Authors:  A S Rocha; P Soares; E Fonseca; J Cameselle-Teijeiro; M C Oliveira; M Sobrinho-Simões
Journal:  Histopathology       Date:  2003-06       Impact factor: 5.087

10.  Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas.

Authors:  Hui-Chun Chen; Ricky Y Chu; Ping-Ning Hsu; Ping I Hsu; Jau-Yeong Lu; Kwok-Hung Lai; Hui-Hwa Tseng; Nan-Hua Chou; Ming-Shyan Huang; Ching-Jiunn Tseng; Michael Hsiao
Journal:  Cancer Lett       Date:  2003-11-10       Impact factor: 8.679

View more
  5 in total

1.  BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Authors:  Neslihan Kurtulmus; Mete Duren; Umit Ince; M Cengiz Yakicier; Onder Peker; Ozlem Aydın; Ender Altiok; Serdar Giray; Halil Azizlerli
Journal:  Endocrine       Date:  2012-03-17       Impact factor: 3.633

2.  Association between E-cadherin (CDH1) polymorphisms and pancreatic cancer risk in Han Chinese population.

Authors:  Lei Zhao; Ying-Xue Wang; Mian Xi; Shi-Liang Liu; Peng Zhang; Li-Ling Luo; Meng-Zhong Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies.

Authors:  Lin Wang; Guiying Wang; Chenqi Lu; Bo Feng; Jiuhong Kang
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

4.  Might E-cadherin promoter polymorphisms of rs16260 and rs5030625 associate with the risk of nephrolithiasis?

Authors:  Cigdem Donmez; Ece Konac; Batuhan T Aydogan; Cenk Y Bilen
Journal:  Springerplus       Date:  2016-09-29

5.  Correlation between SNPs in CDH1 and gastric cancer in Chinese population.

Authors:  Yijin Lin; Jintao Yuan; Lihui Wang; Lan Wang; Yunjia Ma; Yuhua Wang; Jianhong Chen; Hong Zhao
Journal:  Open Med (Wars)       Date:  2014-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.